Sleep Sci. 2015 Jan-Mar; 8(1): 42–48.
Published online 2015 Mar 20. doi: 10.1016/j.slsci.2015.03.001
Luciana B.M. de Godoy,a Luciana O. Palombini,a,⁎ Christian Guilleminault,b Dalva Poyares,a Sergio Tufik,a and Sonia M. Togeiroa
In summary, therapeutic data about UARS treatment are few and consists of CPAP, oral device, surgery and external nasal device. There are no UARS cohorts with long-term treatment and follow-up available. Most studies about UARS treatment are observational and case reports. There were only two randomized double-blind, placebo-controlled studies published. Indeed, most studies have an inadequate methodology with a small number of patients and without precise sample estimation.
Mild SBD criteria and events identification have been subject of discussion. The diagnosis of UARS is still controversial. Currently, UARS is considered part of Obstructive Sleep Apnea Syndrome (OSAS) by the AASM. OSAS is defined as the presence of more than 5 obstructive events per hour associated with symptoms or more than 15 events per hour independent of symptoms. Currently, there is no data with outcomes available defining the cut off limit for RERAs and Respiratory Disturbance Index (RDI) in SBD patients, as well as, on healthy individuals. Respiratory index, such as, apnea/hypopnea index (AHI) and RDI has been used with different definitions and considering different respiratory events. There are still several issues that need to be better defined and established regarding UARS, however, most authors today agree that sleep breathing disorders cannot be limited just to OSAS criteria.
CPAP is the UARS treatment modality better investigated. [1,23,24] One month of therapeutic trial with nasal CPAP can significantly change objective polysomnographic parameters  and subjective complaints. [1,23,24] CPAP treatment was associated to decrease in transient arousals, increase in percentage of NREM stages 3 and 4 and the sleep latency at MSLT.  Subjective daytime sleepiness, fatigue [1,23] and snoring  also can improve after CPAP treatment. Nevertheless, in some studies there were patients that did not have their excessive daytime sleepiness and fatigue decreased after CPAP treatment . Consequently, these patients did not comply with CPAP due to the lack of beneficial effects . Even though CPAP may be an effective treatment for UARS, the compliance is low in this patient population. Also, in follow up studies a significant part of patients did not use the recommended nasal CPAP treatment due to refusal by the insurance companies to cover its prescriptions, on the basis that according to their policies, UARS did not meet the criteria for a CPAP prescription .
Auto-CPAP was indicated to treat pregnant women with severe preeclampsia and flow limitation . The mean overnight blood pressure was markedly reduced during the night of treatment with nasal CPAP when compared with the nontreatment night. The authors suggest that nasal CPAP may be considered as a therapy to improve blood pressure control in women with severe preeclampsia and flow limitation.
Medications that decrease sleep fragmentation could be also helpful for UARS patients. 7.5 mg Zopiclone during 1 week produced significant improvements in the sleep efficiency index and average sleep latency in MSLT . Nevertheless, it had no effect on respiratory parameters during sleep and daytime sleepiness in patients with UARS. Despite some improvements demonstrated objectively in the polysomnography, Zopiclone use did not decrease UARS symptoms. It was concluded that medications that consolidate sleep could be an adjuvant medicine used during the main treatment of UARS patients.
Sleep fragmentation persists in many patients with insomnia despite an adequate insomnia treatment. The sleep fragmentation associated with UARS can cause daytime fatigue and enhance anxiety, factors that can increase the difficulty in treating chronic insomnia. Postmenopausal women with chronic insomnia and UARS had their daytime fatigue decreased after nasal treatment (nasal radio-frequency ablation of turbinate or septoplasty with turbinectomy) and nasal CPAP-treatment . This study reinforce the idea that SBD should be investigated in patients with chronic insomnia to guarantee an adequate insomnia treatment result.
Psychiatric patients may also present SDB. A case report about a young man with treatment-resistant depression and with sleep symptoms (insomnia, fatigue and daytime sleepiness) was investigated for SDB . As his psychiatric symptoms were not well controlled despite an adequate medical treatment and he had sleep complaints he underwent a sleep study that showed UARS. The patient was submitted to rapid palatal expansion and during the two-year follow-up remained free from symptoms of depression, anxiety, sleepiness or fatigue in the absence of any psychotropic medication, although there were no statistically significant changes in the polysomnographic parameters. This article reinforces the idea that a sleep study should be included and SBD should be investigated in psychiatric patients who have persistent sleep complaints and whose psychiatric symptoms are not controlled despite an adequate medical treatment.
Upper airway surgeries have also been evaluated as UARS treatment option. Craniofacial abnormalities that may increase upper airway resistance are often present in UARS. Dental malocclusion and elevated ogival hard palate as well as a narrow posterior airway space can be frequent findings in upper airway examination . Surgical treatment were studied as an option for patients who cannot tolerate or are unwilling to adhere to CPAP therapy . Some authors studied UARS patients that preferred surgery (such as septoplasty, turbinate reduction, laser-assisted uvuloplasty – LAUP, uvulopalatopharyngoplasty, genioglossus bone advancement, mandibular osteotomy with tongue advancement and hyoid miotomy with suspension) rather than CPAP [29–31]. Sleep studies were performed from 3 to 6 months after treatment [29–31]. The only outcome evaluated in these studies were subjective sleepiness [29–31] and snoring [30–31] and the follow-up was not long enough to consider surgery a long-term effective management for this group of patients.
Many authors agreed that procedures should address anatomical regions that cause upper airway obstruction and that UARS treatment consists of approaching the causes of the upper airway anatomical problems such as treatment of nasal allergies, usage of palatal soft-tissue surgeries, orthognatic surgery or use of dental devices [6,40,41,42,43,44]. Some authors had even tried to formulate a statistical model for postoperative AHI after multilevel surgery in UARS patients . It was concluded that tonsillectomy had a highly significant influence on postoperative AHI.
Concluding, few studies evaluating surgical treatment for UARS are available. Most studies about surgery treatment only consider subjective outcomes and the number of patients has been too low to lead to conclusive results. Many methodological problems in published literature did not allow a proper analysis [45,46]. Randomized prospective protocols of surgical procedures should be conducted.
Another treatment option for SDB is the use of oral devices. Oral devices move the mandible and tongue forward in order to minimize the oropharyngeal obstruction. Patients with UARS present a narrow posterior airway space behind the base of the tongue. Oral devices increase upper airway dimensions and are often indicated for mild SBD. There are some case reports [33–36] and a prospective study  published about oral device as UARS treatment. Some authors noticed polysomnographic differences, such as a decrease in the total arousal index (TAI) [33,34,37], a less negative mean Pes [33,34], an improvement in sleep efficiency  and lower oxygen saturation . A significant increase in the mean sleep latency in the MSLT [34,35] and an absence of sleep during the Maintenance of Wakefulness Test (MWT) was also observed . Oral appliance also decreased subjective daytime sleepiness [33,37] and snoring . Another study report a case of oral appliance indicated for an asthmatic patient with UARS that had poorly controlled asthma symptoms despite high-doses steroids . The post-treatment polysomnography showed normalization of the Pes and decrease in the TAI. Even the asthma symptoms were better controlled and lower doses of drugs were required after the oral device treatment.
The side effects of oral devices observed (excessive salivation and transient tooth discomfort) were minor and tolerable, and no major complications were reported . Objective and subjective aspects of the treatment response were evaluated during a longer follow up. The results demonstrated that oral appliance was effective in decreasing sleep fragmentation and objective and subjective daytime sleepiness and was also well tolerated.
Other types of oral devices besides the mandibular advancement device were also published as case reports but the study did not report clinical or polysomnographic changes pre- and post-treatment .
Nasal obstruction is another cause of flow limitation and can lead to occlusion of the pharyngeal airway. The decrease in nasal resistance might also reduce the inspiratory effort. A double-blind, randomized, controlled trial with a cross-over design study was performed to evaluate the effect of external nasal dilatation in UARS patients . The external nasal dilator significantly increased nasal cross-sectional area, reduced stage 1 sleep and decreased desaturation time when comparing to the placebo treatment. These were the only changes observed after treatment. There were no significant effects on the MSLT, AHI or TAI or on the clinical complaints. The absence of significant clinical changes after treatment, despite the polysomnographic differences, demonstrated that this device, currently, cannot be recommended for the treatment of UARS. Future studies with a larger number of patients and with a longer follow-up should be conducted to better analyze this device׳s effects on UARS patients.
Currently, there are few well designed studies available of UARS treatment, CPAP has been the primary therapy prescribed, but its effectiveness has been limited because of low patient compliance and there are no randomized controlled trials evaluating this type of treatment in UARS patients. The available studies that have evaluated surgical treatments of UARS patients have methodological limitations and low numbers of patients evaluated. Oral appliances seem to be an effective option, but only case reports and small case series have been reported, and the efficacy of these devices is not yet established for this group of patients. Randomized controlled trials comparing different modalities of treatment with larger numbers of patients and including long-term follow-up are important to better define and establish treatment options in UARS patients.
The Upper Airway Resistance Syndrome
Pépin J.L.a, b · Guillot M.a, b · Tamisier R.a, b · Lévy P.a, b
Obstructive sleep apnea syndrome has been recognized as a major public health problem. Both its cardiovascular and metabolic comorbidities and symptoms motivate for an accurate diagnosis and appropriate treatment. The main stimulus associated with obstructive sleep apnea (OSA) and explaining deleterious consequences is intermittent hypoxia. The upper airway resistance syndrome (UARS) has been described based on the hypothesis that snoring and repetitive occurrence of respiratory effort-related arousals (RERAs) but not oxygen desaturation might produce a significant disease with symptoms, altered quality of life and cardiovascular morbidity. Diurnal sleepiness remains the main diagnostic criteria, which is often confounded with tiredness in women. UARS patients may also report insomnia and symptoms that closely resemble those of the functional somatic syndromes. Currently, the International Classification of Sleep Disorders does not individualize UARS as a specific entity and reports UARS patients as a subgroup of OSA. However, RERAs are described as unambiguous abnormal respiratory events occurring during sleep and requiring a specific scoring. In this review, the authors attempt to describe the specific characteristics of UARS that are relevant for both clinicians and researchers.
Since the obstructive sleep apnea syndrome (OSAS) has been recognized as a major public health problem [1,2], many efforts have been made to define and understand this syndrome . Breathing abnormalities during sleep are not limited to patients exhibiting typical obstructive apnea but include a continuum of events from simple snoring to OSAS that constitute a group of diseases named sleep breathing disorders. The upper airway resistance syndrome (UARS) was initially reported by Guilleminault et al.  in 1993. This particular syndrome has been described based on the hypothesis that repetitive increases in respiratory efforts that are inducing arousals might produce a significant disease leading to daytime sleepiness and functional symptoms and is associated with cardiovascular and cognitive morbidities. The definitions of sleep breathing disorders published by the American Academy of Sleep Medicine (AASM) Task Force  in 1999 did not include UARS as a syndrome but precisely described respiratory effort-related arousals (RERAs). There is still a debate about the true existence of UARS as a specific disease and regarding cardiovascular consequences that might be attributed to RERAs . The International Classification of Sleep Disorders (ICSD II), published in 2005, is overall in accordance with the AASM Task Force  report published in 1999. Events associating an absence of oxygen desaturation despite a clear drop in inspiratory flow, increased respiratory effort and a brief change in sleep state or arousal are defined as RERAs. The UARS is a proposed diagnostic classification for patients who exhibit RERAs but do not also have events that would meet definitions for apneas and hypopneas. RERAs are presumed to have a similar pathophysiology to obstructive apneas and hypopneas (upper airway obstruction) and are believed to be as much of a risk factor for symptoms of unrefreshing sleep, daytime somnolence, and fatigue as frank apnea or hypopnea. Therefore, ICSD II recommends that UARS should be included as part of OSA and not considered as a separate entity .
UARS is defined by the occurrence of excessive daytime sleepiness unexplained by another cause and associated with more than 50% of respiratory events that are nonapneic and nonhypopneic (i.e. RERAs). RERAs are characterized by a progressive increase in respiratory effort. This may be assessed by direct measurement of esophageal pressure or by another marker of respiratory effort such as the changes in pulse transit time (fig. 2). RERAs may induce both cortical and autonomic arousals  and potentially lead to cardiovascular activation. Respiratory flow, when using nasal cannula or a pneumotachograph, exhibits only qualitative change named inspiratory flow limitation. This is of interest since inspiratory flow limitation results from the progressive increase in upper airway (UA) resistance . Flow limitation is a physiologic phenomenon that can be identified from the nasal pressure signal thus allowing noninvasive detection of RERAs . The time sequence of these obstructive respiratory events is close to what occurs with apneas and hypopneas, but the duration may be longer. This should be distinguished from episodes of sustained stable flow limitation occurring during slow wave sleep. This late flow-limited aspect does not lead to repeated arousals and thus differs from RERAs.
To qualify as an individual disease, UARS should meet the following criteria:
• first, to exhibit specific clinical and polysomnographic diagnostic criteria;
• second, these specific criteria should not be found in the general population;
• third, a direct relationship should be found between this syndrome and a specific morbidity.
UARS Prevalence and Specific Clinical Characteristics
Snoring is reported to be present in 41% of the general population aged between 26 and 50 years. In this cluster of the population, 15% exhibit an apnea-hypopnea index of more than 15 events per hours of sleep . Snoring is reported in 71% of men and 11% of women exhibiting UARS . In a retrospective review of all polysomnographies performed in an academic military sleep disorder center during the year 2000, the prevalence of UARS was 8.4% . The true prevalence of UARS in the general population is unknown and pure UARS is rather rare in clinical practice. UARS patients were significantly younger, less overweight and had lower weight gain during the past 5 years compared to OSA patients . The female-to-male ratio seems to be highest in the UARS group.
Diurnal sleepiness remains the main diagnostic criteria, which is often confounded with tiredness in women. Twenty percent of UARS patients may report insomnia. All other OSAS clinical criteria may apply to UARS such as nocturia, nocturnal awakening, sleep inefficiency, and cognitive impairment. Headaches, vasomotor rhinitis, and irritable bowel syndrome have also been described as more frequently associated with UARS [12,13]. The symptoms of UARS, then, closely resemble those of the functional somatic syndromes. Several authors argue about the fact that these symptoms are not specific enough compared to OSAS and are quite similar to those reported during chronic asthenia .
Psychological complaints are also reported, such as difficulty in concentrating and depressive mood . Patients with UARS are most impaired in terms of their daily functioning and perception of sleep quality. Accordingly, these patients seem to consume more hypnotics, antidepressants or stimulants if they are not treated.
Owing to the lack of specificity of the reported symptoms, the question is to know whether these complaints are corroborated by objective measures. When measuring the tendency to fall asleep by multiple sleep latency tests in 137 UARS, Gold et al.  reported that UARS patients frequently complained about sleepiness but were objectively less sleepy compared to mild-to-moderate and severe OSAS patients.
Powers and Frey  measured maintenance wakefulness tests in 19 UARS patients and found that 33% of them exhibited a mean sleep latency below 19.4 min (i.e. <2 SD below normal values). Psychomotor performances assessed by measurements of reaction time have been compared in 47 UARS matched by gender and age with 47 OSAS patients .
Patients with UARS presented worse psychomotor performance on most test metrics than patients with OSAS. These results may suggest that patients with UARS may also present an increased risk of motor vehicle crashes as previously demonstrated in OSAS patients .
Regarding clinical examination, some craniofacial characteristics were reported as being specific to UARS . These patients exhibit the classical long face syndrome with a short and narrow chin and reduced mouth opening (fig. 1). There is classically a ‘click’ and a subluxation when opening the temporo-mandibular articulation, which may be evidenced by palpation. The mandible is in the back position and the palate is high and narrow.
Finally, Guilleminault et al.  have described a low-resting arterial blood pressure or orthostatic intolerance as occurring in one fifth of subjects with UARS.
Typical craniofacial features in UARS patients. Representative patients suffering from UARS with classical craniofacial abnormalities, i.e. long face syndrome with a short and narrow chin and with the mandible in the back position (a, b). c During clinical examination, dental overjet and ogival hard palate are typical features of UARS [modified from .
UARS may also need to be considered in severely obese young patients . These authors reported a high prevalence of UARS (about 15 to 20% based on polysomnographic criteria). We found similar results in a population of severely obese patients who were referred for consultation without sleep complaints [Tamisier, unpubl. data]. The physiopathology of UARS in these patients may deserve some discussion as the repetitive RERAs they experienced might not only be a consequence of UA collapse but may reflect the increase in respiratory work due to reduced thoracoabdominal compliance. However, polysomnographic criteria are close to those used in young lean UARS patients.
Regarding the evolution of the disease, the severity of UARS remains stable over time . The progression from UARS to OSAS seems to be related to an increase in the body mass index .
Particularities of Polysomnographic Patterns and Diagnosis
RERAs and arousal detection are the key elements during sleep monitoring (fig. 2). RERAs correspond to a sequence of breaths characterized by increasing respiratory effort leading to an arousal from sleep, but which does not meet criteria for an apnea or hypopnea in terms of flow reduction. These events must fulfill both of the following criteria: (1) a pattern of progressively more negative esophageal pressure, terminated by a sudden change in pressure to a less negative level and an arousal, and (2) the event lasts 10 s or longer. The number of events may be underestimated when tools used during this monitoring are not appropriate. By definition, detection of RERAs is based on accurate flow measurement using the nasal cannula or a pneumotachograph  and respiratory effort measurement using either oesophageal pressure or pulse transit time [3,22,23]. By using a nasal thermocouple to detect flow a shift between hypopnea to RERA will occur and an authentic OSAS will be misdiagnosed to a UARS. This has been described by Montserrat and Badia  as the ‘thermistance syndrome’. We investigated subjects presenting with sleep-disordered breathing and very little oxygen desaturations, thus being either mild OSAS or UARS, using the reference tools (pneumothachograph and esophageal pressure). They exhibited mainly hypopneas but we found only about 5% of true RERAs . RERAs must be considered as specific respiratory events expressed by patients depending on their UA collapsibility. To this extent, it is logical to include RERAs in the respiratory disturbance index.
Representative pattern of RERAs during a sleep study. The figure depicts the recurrence of RERAs with a progressive flow limitation aspect on nasal cannula which corresponds to an increase in respiratory effort (both esophageal pressure and pulse transit time). The consequences of these events are both sleep fragmentation (frank autonomic arousal on the first and third events) and arterial blood pressure rises.
The detection of RERAs requires a reliable measure for respiratory efforts. In adults, pharyngeal and/or esophageal pressure  and variation of pulse transit time are usually reliable enough to be used in this way [22,23,26]. An optimal evaluation of inspiratory flow limitation may be used to detect RERAs . However, two limitations need to be mentioned. First, inspiratory flow limitation is an indirect consequence of respiratory effort and may be less accurate in REM sleep. Second, reliability of analysis requires a good flow signal quality which may depend upon both hardware and software. Inspiratory flattening of time derivatives of respiratory-inductive plethysmography volume signals and marked ribcage/abdominal asynchrony may also allow differentiating UA resistance episodes from simple snoring [27,28]. A computer-assisted analysis of respiratory-inductive plethysmography has been proposed to improve the detection of such events .
Sleep fragmentation may be quantified by direct arousal detection using electroencephalographic measures following the specific American Sleep Disorders Association (ASDA) criteria  or using autonomic tools like pulse transit time .
The pharyngeal collapse depends on the balance between collapsible factors like UA narrowing , pharyngeal collapsibility and protective factors like UA-dilating muscle activity and the protective pharyngeal reflexes . Patients with UARS are less obese than OSA patients and exhibit typical craniofacial abnormalities (see above) leading to a size reduction of the pharynx. Obstructive respiratory-event severity is not related to differences in respiratory effort magnitude as assessed by esophageal pressure crescendo, but rather to a different UA collapsibility . Depending upon UA collapsibility and UA protective mechanisms, a given patient exhibits a variable combination of abnormalities among the full spectrum of obstructive respiratory events. Collapsibility can be anticipated by measuring critical pressure during sleep. Critical pressures in UARS are in intermediate values between OSAS and normals: –4.0 ± 2.1, –1.6 ± 2.6 and –15.4 ± 6.1 cm H2O, respectively [34,35]. Using negative expiratory pressure, we also confirmed a reduced UA collapsibility in UARS when compared to OSAS . As a consequence, when measuring UA resistances, UARS patients are able to maintain higher levels of UA resistance in any sleep stage compared to OSAS patients  (fig. 3). This intermediate UA collapsibility is associated with flow limitation or UA resistance events instead of apneas for the same level of respiratory effort in OSAS exhibiting severe UA collapsibility (fig. 3) [7,37]. The ability of UARS patients to maintain UA opening at high levels of UA resistance is partly explained by more preserved protective reflexes of the pharynx. Two studies have demonstrated that UARS subjects exhibit UA sensitivity close to normals [38,39]. As UA sensitivity is not impaired in UARS, these patients are able to activate the protective reflexes with the consequence of very high levels of dilating muscle activity explaining the facility to counteract high levels of UA resistances.
Specific pathophysiology of UARS [modified from ]. a When measuring UA resistance, UARS is able to maintain higher levels of UA resistances in any sleep stage compared to OSAS. OSH = Obstructive sleep hypopnea; SS = simple snorers. b Relative proportion of apnea-hypopnoea (AHI) and high-resistance episodes (RERA index: HRI) indices in 3 groups of patients with UARS, and moderate and severe OSAS. In these subgroups of patients, the absolute number of respiratory events did not differ significantly. However, the amount of high collapsibility events (i.e. apnea and hypopnea) and low collapsibility events (i.e. RERA) depend upon the sleep disorder exhibited by the patient. Patients with UARS exhibit predominantly RERA and hypopnea, while severe OSAS patients exhibit mostly apneas in relation to their UA collapsibility status. W = Wake.
UARS-Associated Cardiovascular Comorbidities
Obesity and intermittent hypoxia play a major role in explaining cardiovascular and metabolic consequences associated with sleep apnea . UARS patients are less obese than OSAS patients and by definition do not reveal severe oxygen desaturation during sleep. The remaining mechanisms that might link UARS to cardiovascular and metabolic consequences are snoring, increased respiratory efforts throughout the night and sleep fragmentation.
Recent studies have underlined the potential role of snoring per se in the development of carotid atherosclerosis. Lee et al. [41 ]reported data in an observational cohort of 101 snorers and non-snorers with mild nonhypoxic obstructive sleep apnea hypopnea syndrome. Heavy snoring (>50% night snoring), diagnosed on PSG, was an independent factor for carotid atherosclerosis. This factor was a stronger predictor for carotid atherosclerosis than age, sex, smoking history, or hypertension. Convincingly, the prevalence of carotid atherosclerosis increased progressively according to the severity of snoring. The mechanism for the association is supposed to be purely mechanical, i.e. snoring vibrations may be transmitted through the surrounding tissues to the carotid artery wall, inducing endothelial damage and finally leading to carotid atherosclerosis. Carotid bifurcation is effectively the major site of carotid artery atherosclerotic plaques and is in close proximity to the hypopharyngeal wall. In the same population, femoral atherosclerosis was not observed whatever the snoring severity, which suggests that snoring is acting only mechanically at the carotid level. Even more recently, the role of pericarotid tissue vibration as able to induce carotid artery endothelial dysfunction and structural changes has been confirmed by the same group of authors in an animal model .
In UARS, the second key mechanism underlying cardiovascular consequences is the occurrence of repetitive micro-arousals ending the RERA episodes. Guilleminault et al.  firstly described repetitive increases in blood pressure as a result of airway resistance episodes during sleep. As depicted in figure 2, every micro-arousal is accompanied by an abrupt surge in blood pressure. UA resistance episodes without desaturation are easy to reproduce using suboptimal continuous positive airway pressure (CPAP) in CPAP-treated OSAS patients. Using this experimental setting, it has been demonstrated that long-lasting flow limitation episodes induce not only acute changes in blood pressure but also a small increase in PetCO2 (fig. 4).
It is well established that any increase in CO2 also stimulates the activity of the sympathetic nervous system. Sleep fragmentation by arousing normal healthy humans from sleep over 2 nights (30–40 times/h) was also able to cause a 20% decrease in the insulin sensitivity . Consequently, UARS-induced sleep fragmentation and prolonged episodes of inspiratory flow limitation might lead to a chronic increase in sympathetic outflow that could explain the secondary occurrence of hypertension, and cardiovascular and metabolic consequences.
However, few data actually exist to relate UARS to cardiovascular consequences [43,46,47]. Lofaso et al.  reported that nonapneic-nonhypopneic obstructive events are followed by arterial systemic pressure increases whose magnitude varies with the grade of the arousal. Accordingly, Lofaso et al.  studied 105 middle-aged nonapneic snorers and found that systemic hypertension was significantly higher in the sleep-fragmented group (i.e. UARS).
Orthostatic hypotension has also been associated with UARS  but large epidemiological studies focusing on the cardiovascular consequences of UARS are lacking. Overall, even though there are some mechanistic hypotheses, the degree of evidence to support a significant cardiovascular morbidity in UARS is very limited.
UA resistance episodes are associated with blood pressure fluctuations and rises in CO2. UA resistance episodes are easy to reproduce by using suboptimal CPAP in CPAP-treated OSAS patients. It has been demonstrated in this situation that long-lasting flow limitation episodes induce not only acute changes in blood pressure but also a small increase in PetCO2 [modified from ].
UARS Treatment Strategy
Therapeutic data are few and no UARS cohorts with long-term treatment and follow-up are available. CPAP has been used to evaluate the potential improvements that can be obtained regarding functional outcomes . Compliance to treatment is limited in the subgroup of UARS. However, since several studies have demonstrated CPAP efficacy in mild OSAS, CPAP should also be considered as an appropriate treatment for UARS.
As many patients exhibit maxillofacial abnormality, surgery appears a logical indication. To our knowledge, no surgical study has specifically targeted UARS patients. Furthermore, no evaluation exists for laser-assisted or radiofrequency surgery in this specific indication.
As these patients are lean and frequently present with retrognathia, the use of mandibular advancement devices is a commonsense decision, with the advantage of being reversible where surgery is not . However, a large study in the specific indication of UARS with appropriate outcome evaluation is required.
UARS is a relatively rare condition. Patients are presenting with excessive daytime sleepiness and functional somatic syndromes. The pathophysiology is specific with a relatively low collapsibility of the UA and preserved pharyngeal reflexes. Diagnosis during sleep studies requires the use of appropriate tools for measuring respiratory effort (i.e. esophageal pressure or pulse transit time). There is a need for more clinical and translational research to determine whether sleep fragmentation alone can contribute to the development of cardiovascular and metabolic consequences . UARS may persist without further evolution towards apneic events except in the case of weight gain. Oral appliances represent the best therapeutic option when feasible. Unfortunately, the studies of UARS patients have been largely observational. No evidence from randomized studies is available that would underpin a causal relationship between the physiologic observations made in patients with the syndrome, specific symptoms and cardiovascular consequences. The treatment strategy is still an expert opinion.